Koka Life Science's PIONEER TAVR System Gains NMPA Approval with World-First 3D Steerable Technology

Recently, the National Medical Products Administration approved Kokai (Nantong) Life Sciences Co., Ltd. (hereinafter referred to as: Kokai Life Sciences)Transcatheter Aortic Valve SystemThe registration application of this innovative product has been approved, marking the official launch of another domestically produced innovative TAVR product in China.

Image Source: NMPA Official Website

01

Innovation and R&D

3D Spatial Bending Technology

Kokai Life Sciences was founded in September 2018, and has always focused on the field of structural heart disease. It develops systematic solutions for valve diseases across different populations, needs, and scenarios. After years of development, Kokai Life Sciences' research and development capabilities, experience, and technology are all at the forefront in China.

According to the PharmCube medical device data query, Kokai Life SciencesFive products have been successfully approved for marketing(The following figure does not include the product approved for marketing this time), among whichTwo products are innovative medical devices., showcasing the strong innovative R&D capabilities of Kokai Life Sciences.

Image Source: Yaoke Medical Device Data

The innovative medical device approved for marketing this time isTranscatheter Aortic Valve SystemThe product consists of an aortic valve, an aortic valve delivery system, and a valve loading device. It is suitable for elderly patients aged ≥70 years who, after assessment by a cardiac team using a scoring system, are still considered to have symptomatic severe aortic valve regurgitation (severe aortic valve insufficiency) and are not suitable for conventional surgical valve replacement.

It is worth mentioning that, according to Kokai Life Sciences,PIONEER TAVR Transcatheter Self-Expanding Aortic Valve System Features a Core Technological Breakthrough —— The World's First 3D Spatial Bending Adjustment TechnologyThanks to this technology, the transcatheter self-expanding aortic valve system has also gained the product advantage of precisely delivering the valve to the designated position. It addresses the major core challenge of coaxiality in treating pure aortic regurgitation via the femoral artery, and its design...3 controllable positioning components, it can also significantly reduce coronary risks. During the clinical trial phase, the system has demonstrated excellent performance.

Another innovative medical device isTranscatheter Mitral Valve Repair System, was approved on May 27, 2025. This product isThe World's FirstFull-size specifications and full-clip self-locking mitral valve clips, suitable for patients with degenerative mitral regurgitation (MR≥3+) who are assessed by the heart team as having a high surgical risk and whose mitral valve anatomy is appropriate.

In addition, Kokai Life SciencesCompleted 3 rounds of financingThe highest single financing amount reached 350 million yuan. According to the introduction, most of the financing funds are used for the advancement of large-scale clinical trials for existing heart valve projects, continuous investment in valve clinical applications and validation trials, and the progress of subsequent innovative product pipeline research and development. Moreover, according to Yaozhi Patent, Kokai Life Sciences is currently...More than 200 authorized patents, most of the authorized patents revolve around valve products.

Source of the image: Yaoke Data - Investment Landscape Database

02

Rise to the Challenge

Create Differentiated Advantages

Transcatheter Aortic Valve Replacement (TAVR), as a revolutionary technology in the current interventional field, has become one of the fastest-growing segments in the global medical device market.

According to Frost & Sullivan data,The global TAVR market size is expected to reach $10.4 billion by 2025., with a compound annual growth rate of 14.3%. In terms of the global TAVR regional distribution and development status, the North American market occupies a dominant position and is expected to account for more than 42.5% of TAVR market revenue.

Among them,The U.S. market stands out in particular., the number of TAVR procedures has already surpassed that of traditional surgical aortic valve replacement (SAVR). The Asia-Pacific region is considered to have the greatest growth potential and is expected to become the fastest-growing market during the forecast period, with China's potential being particularly prominent.

Although currently in the Chinese market,The penetration rate of TAVR remains low, far below the global level., a large amount of demand has not been met, with broad prospects. However, influenced by factors such as the intensification of population aging, further improvements in medical standards, and the increase in TAVR surgery penetration rate (expected to reach 10.2% by 2030), the scale of China's TAVR marketExpected to reach 11.36 billion yuan by 2030, will become an important growth point in the field of heart valve intervention.

According to the PharmCube MedTech data,Currently, more than 10 TAVR series products have been launched in China.(The query data includes some products used in conjunction), among whichThe quantity of domestically produced products has reached 66.67%., such as MicroPort CardioFlow and Venus MedTech, are further accelerating their布局 in the TAVR sector. Currently, domestically produced TAVR products include achievements like the TaurusOne® Transcatheter Aortic Valve System, VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System, among others, which have successively come to fruition.

Image Source: PharmCube Medical Device Data

It is worth noting that the overall TAVR market currentlyStill dominated by global medical device giants such as Edwards Lifesciences and Medtronic., and medical device giants are also continuing to invest heavily and make significant bets on this track, with multiple achievements reaching the global market.

However, domestic medical device companies are also continuously increasing their innovation and R&D efforts.Create differentiated advantages in multiple directions such as technological innovation breakthroughs and solving pain points and difficulties of existing products., solving the technical challenges of traditional TAVR systems in such cases, opening up a unique market space, and further increasing market share.

03

Conclusion

With the approval of another重磅product from Kokai Life Sciences, the TAVR sector in China has gained another innovative product, showcasing its差异化advantages.

Reference Source:

1. Technical Policy News | Entering the Innovation Pathway! Transcatheter Self-Expanding Aortic Valve Membrane Made in China - Sichuan Western Medical Technology Transfer Center